https://americanmigrainefoundation.org/resource-library/new-migraine-treatments/
New Acute Migraine Treatments Oral Medications. Triptans are commonly used for immediate migraine relief, but advancements in migraine research have led to the discovery of other oral medications, such as gepants, which are medications that target and reduce CGRP (calcitonin gene-related peptide, a protein that causes inflammation in the brain).. Another new class of medications is the ditans

https://www.cnn.com/2023/03/10/health/migraine-nasal-spray-zavzpret/index.html
CNN —. The US Food and Drug Administration approved a new nasal spray as a rapid treatment for migraine pain in adults. The nasal spray zavegepant, sold as Zavzpret, may relieve pain and other

https://www.healthline.com/health/migraine/migraine-treatment-latest-advances
Standard treatments taken at the onset of a migraine episode (also called acute or abortive treatment) include oral medications, such as: over-the-counter analgesics (pain relievers), such as

https://www.webmd.com/migraines-headaches/migraines-new-treatments
The newest acute drugs include: 5-HT1f drugs such as lasmiditan (Reyvow) work on pain pathways and stop pain and other bothersome migraine symptoms. Side effects include dizziness, fatigue, and a

https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/
The newest oral drugs for the acute treatment of migraine are Nurtec ODT ( rimegepant) and Ubrelvy ( ubrogepant ), both orally-administered calcitonin gene-related peptide (CGRP) receptor antagonists (gepants). Another new drug for the acute treatment of migraine is Reyvow ( lasmiditan ), the first serotonin (5-HT) 1F receptor agonist.

https://www.fda.gov/news-events/press-announcements/fda-approves-novel-preventive-treatment-migraine
Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
December 23, 2019. The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine
For Immediate Release: October 11, 2019. The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or

https://www.verywellhealth.com/migraine-drug-fda-approval-5188517
The FDA has approved the first drug that can both treat and prevent migraines. Nurtec ODT was initially approved for acute use—to treat an existing migraine—in February of last year. According to experts, there are now many medications and products available to help people prevent their migraines. For years, people who experience migraine

https://www.nbcnews.com/health/health-news/fda-approves-new-fast-acting-nasal-spray-migraines-rcna74356
The new drug isn't the first nasal spray for migraines, although Dr. Emad Estemalik, a headache specialist at the Cleveland Clinic, said the quick, 15-minute relief gives the drug an advantage

https://www.verywellhealth.com/cgrp-therapies-migraine-drug-guidance-8619509
Key Takeaways. CGRP inhibitors have been elevated to a first-line prevention method for migraine, according to the American Headache Society. The first CGRP for migraine prevention was approved in 2018. The medications can be used along previous first-line treatments for migraine. In a significant development, the American Headache Society (AHS

https://mcpress.mayoclinic.org/migraine/advances-in-migraine-treatment/
Ubrogepant (Ubrelvy) and rimegepant (Nurtec ODT) are new CGRP receptor antagonists for as-needed treatment of migraine that do not narrow blood vessels. These oral medications block the CGRP receptor to hopefully stop a migraine attack that is already ongoing. More research is needed, but these drugs don't appear to have the same risk of

https://www.vox.com/even-better/2024/1/11/24027133/headaches-migraines-treatment-gepants-health-care
There's good evidence that riboflavin, otherwise known as vitamin B2, prevents migraines in some people and has few side effects; magnesium may also be helpful, although it can cause unpleasant

https://abcnews.go.com/Health/fda-approves-pfizers-new-nasal-spray-treatment-migraines/story?id=97749225
A Pfizer logo is seen in Krakow, Poland, Dec. 8, 2022. The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) -- the first and only

https://healthcare.utah.edu/healthfeed/2023/08/whats-new-migraine-treatment
CGRP Monoclonal Antibodies. Since 2018, there have been a number of breakthroughs in migraine treatment. The first drugs approved by the Food and Drug Administration (FDA) were a new class called monoclonal antibodies that target calcitonin gene-related peptide (CGRP). These drugs prevent migraines before they happen by stopping the release of

https://www.health.harvard.edu/diseases-and-conditions/fda-approves-new-migraine-medication
In October 2019, the FDA approved lasmiditan (Reyvow) to treat migraine pain in adults. Taken as a pill, it works for migraines either with or without an aura (a visual disturbance within the hour before migraine pain starts). Lasmiditan is not designed to prevent migraines. Lasmiditan is the first migraine treatment in a class of drugs known

https://www.bbc.co.uk/news/health-68780240
The first oral treatment for preventing both chronic and episodic migraines could soon be available on the NHS. Health experts said up to 170,000 people in England could benefit from taking

https://www.aarp.org/health/conditions-treatments/info-2024/gains-ease-migraine.html
ORAL MEDICATIONS . The new generation of migraine drugs is called CGRP antagonists (or "gepants"). These drugs — rimegepant (Nurtec), ubrogepant (Ubrelvy) and atogepant (Qulipta) — block the action of a pathway, or connection of brain cells, involved in triggering migraine attacks. Typically, these are used "as needed

https://www.bbc.co.uk/news/health-68780240.amp
Atogepant is a new type of anti-calcitonin gene-related peptide (CGRP) drug, which is specifically designed to treat migraines. They work by blocking the receptor of the CGRP protein. This is

https://www.bbc.co.uk/news/health-66799682
A treatment for migraine attacks which dissolves under the tongue will soon be available on the NHS in what experts say is a "step change" in care. ... A migraine charity said it brought "new hope

https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360207
Migraine treatment is aimed at stopping symptoms and preventing future attacks. Many medications have been designed to treat migraines. Medications used to combat migraines fall into two broad categories: ... Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

https://headacheaustralia.org.au/new-treatments-update/
New Treatments Update. Last updated on 19 August 2022. In this update: A new category of treatments has recently been developed to prevent migraine attacks from occurring. These are the Calcitonin Gene-Related Peptides (CGRP) monoclonal antibodies. We have spoken to our community about these new migraine treatments in the past.

https://www.uptodate.com/contents/acute-treatment-of-migraine-in-adults
INTRODUCTION — Migraine is a common episodic disorder, the hallmark of which is a disabling headache generally associated with nausea and/or light and sound sensitivity. The acute treatment of migraine in adults is reviewed here. Preventive treatment of migraine in adults is discussed separately. (See "Preventive treatment of episodic migraine in adults".)

https://www.verywellhealth.com/migraine-prevention-medication-8660649
You experience disabling migraine attacks, even with treatment. You experience frequent migraine attacks (generally one per week or more). You do not respond sufficiently (or at all) to medications you take to treat a migraine attack (called rescue medications or acute treatments), or you cannot take or tolerate these treatments.

https://www.pharmiweb.com/press-release/2024-06-18/scientists-develop-new-treatment-for-pain-associated-with-sciatica-and-migraines
Scientists develop new treatment for pain associated with sciatica and migraines. Neurolieve Biosciences, a biotech company backed by NLC Health Ventures, is developing a new treatment aimed at improving the lives of those suffering from neuropathic pain. Neuropathic pain is a condition that affects tens of millions around the world.

https://www.nytimes.com/2024/06/03/well/live/covid-symptoms-treatment-flirt-variants.html
The symptoms still include sneezing, congestion, headaches, sore muscles, nausea or vomiting. Many people also report exhaustion and a general "blah" feeling.

https://www.ncbi.nlm.nih.gov/books/NBK507873/
Recurrent migraines can be functionally disabling and can impair quality of life. The disabling nature of migraine headaches leads to frequent visits to outpatient clinics and emergency department facilities, causing significant health and financial burdens. Headaches fall in the top five causes of emergency department visits and the top twenty reasons for outpatient visits.[1] The overall